https://www.saotomeandprincipehealthreport.com/article/871862095-chemomab-therapeutics-announces-nebokitug-phase-2-spring-trial-results-in-primary-sclerosing-cholangitis-published-in-the-american-journal-of
Chemomab Therapeutics Announces Nebokitug Phase 2 SPRING Trial Results in Primary Sclerosing...
https://www.biospace.com/chemomab-therapeutics-announces-new-publications-reinforcing-the-clinical-potential-of-its-ccl24-neutralizing-antibody-cm-101-in-primary-sclerosing-cholangitis
Chemomab Therapeutics Announces New Publications Reinforcing the Clinical Potential of Its...
Jun 18, 2024 - Chemomab Therapeutics Ltd. today announced a new scientific publication that further confirms the important role of the soluble protein CCL24 in the...
new publicationstherapeuticsannounces
https://lifestyle.pierrecountry.com/story/65773/chemomab-therapeutics-to-participate-in-oppenheimer-36th-annual-healthcare-life-sciences-conference/
Chemomab Therapeutics to Participate in Oppenheimer 36th Annual Healthcare Life Sciences Conference...
to participate
https://public.com/stocks/cmmb/earnings
Chemomab Therapeutics (CMMB) Earnings: Latest Report, Earnings Call & Financials
Chemomab Therapeutics reported Miss earnings on Mar 19, 2026 with an EPS of -$0.24 vs. -$0.10. View the full CMMB earnings report, listen to the earnings call,...
latest reporttherapeuticscmmbearningscall
https://finfab.pro/us-stocks/CMMB
Chemomab Therapeutics Ltd. (CMMB) stock price, news, financials - FinFab
Chemomab Therapeutics is a clinical-stage biotech firm that creates medicines for treating inflammation and fibrosis. They're known for CM-101, a humanized...
stock price newstherapeuticsltdcmmbfinancials